Skip to main content
. Author manuscript; available in PMC: 2021 Dec 30.
Published in final edited form as: Precis Cancer Med. 2021 Dec 30;4:38. doi: 10.21037/pcm-21-17

Figure 2.

Figure 2

Depiction of strategies to reduce the occurrence of 5-FU-related toxicities. Pre-treatment screening is used to identify patients at elevated risk for 5-FU-related toxicities due to either polymorphisms in the DPYD gene associated with reduced DPD functional activity or measuring plasma Uracil values from which deficiencies in pyrimidine metabolism can be inferred. Initial 5-FU dosing may be reduced based on pre-treatment screening results. TDM permits 5-FU dose modulation based on plasma 5-FU levels during cycle 1 treatment such that subsequent cycles are more likely to be in the optimal range.